All News

gingivitis_0.jpg

Gingival Inflammation Parallels Saliva “Cytokine Score”

d Jack Cush, MD

Researchers at NYU College of Dentistry have developed a single score to describe the level of cytokines in the saliva, and this score is linked with the severity of clinical gum inflammation, according to a study

Read Article
ANA.Wikipedia.jpg (keep)

New Laboratory Insights for the ANA+ Consult

d Jack Cush, MD

A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).

Read Article
computer screen safety

Drug Safety Differences with New Novel Therapies in RA

d Jack Cush, MD

Safety outcomes for targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) used to treat RA were studied using data from the Anti-Rheumatic Therapies in Sweden (ARTIS) registry, showing that these newer agents are largely similar, but still have particular differences for specific infection or other adverse event risks.

Read Article
Study of 232 pediatric #SLE pts. Over 12 mos 47% achieved LLDAS & Damage seen in 40% after 6.2 yrs F/U. Getting to LLDAS w/in 12 mos is assoc w less damage. LLDAS w/in 12 mos more likely in Absence of renal involvement. https://t.co/pGethJCw4e https://t.co/eYpVueIKbf

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums: Treating #RA, Do you Consider/Use RA Rx guidelines?

Dr. John Cush RheumNow ( View Tweet)

On Dec. 19, 2022, the U.S. Food & Drug Administration (FDA) approved subcutaneous abaloparatide (Tymlos) for the treatment of men with osteoporosis at high risk of fracture https://t.co/igwxVCdKuo https://t.co/COSmDrsv4p

Links:

Dr. John Cush RheumNow ( View Tweet)
Alternatives to Vagal nerve stimulation Dr Eric Ruderman #RWCS23 @RWCSmtg https://t.co/zpJsh10LLQ
Dr. John Cush RheumNow ( View Tweet)
2nd study results with Implantable Vagal nerve stim in active #RA pts. Dr Eric Ruderman #RWCS23 https://t.co/S6aFSVjePD
Dr. John Cush RheumNow ( View Tweet)
Implantable Vagal nerve stimulation studied in 17 active #RA pts DAS ~6. Dr Eric Ruderman #RWCS23 https://t.co/Xn9Ur199nv
Dr. John Cush RheumNow ( View Tweet)
Dr Eric Ruderman #RWCS23 Bee Venom around since 1859, vaguely better than placebo https://t.co/3Xl7SZwQPm
Dr. John Cush RheumNow ( View Tweet)
ADA biosimilars: one is out now and seven due out by July. “It’s time to get onboard with biosimilars” @RheumNow @RWCSmtg #RWCS23

Dr. Rachel Tate uptoTate ( View Tweet)

Do you use TNFi in pregnant patients? @RheumNow #RWCS23 @RWCSmtg

Dr. Rachel Tate uptoTate ( View Tweet)

Low dose prednisolone in RA. GLORIA shows toxicity can be a real issue. @RWCSmtg @RheumNow #RWCS23 https://t.co/KstyKdjWn2
Dr. Rachel Tate uptoTate ( View Tweet)
2022 EULAR recs for RA treatment @RheumNow @RWCSmtg #RWCS23 https://t.co/nWCcFJyIhz
Dr. Rachel Tate uptoTate ( View Tweet)
Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live! Among our 24 speakers, Dr. Sergio and Monica Schwartzman will cover All in the Family Rheumatology. Dr. Philip Conaghan will cover Insights into the Future of OA and more. https://t.co/gAKQYxhTMY https://t.co/zMOGfhRrg2

Links:

Dr. John Cush RheumNow ( View Tweet)
Know Your Numbers! Have a chance to tune in to last week's podcast? https://t.co/A6bYIahvBF https://t.co/ZAgZ3FvL0H

Links:

Dr. John Cush RheumNow ( View Tweet)
Lg vessel US study compared 44 LV-GCA vs 42high-risk atherosclerosis pt.Intima-media thickness (IMT) was signif. higher w/ GCA. IMT ≥ 1 mmseen in 31/44 axillary, 30/44 subclavian in GCA; but only in 2/42 axillary & 3//42 subclavian in atherosclerosis grp.https://t.co/DGMOfflcVR https://t.co/QVBbdrcd3I

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 64 gout pts having orthopedic surgery - perioperative flares more likely with Incr SUA, DM, tophi and diuretics. In 12 mos following surgery, recurrent gout more if ^SUA (45% vs 11%) & those w/ topic ((RR = 4.8; P = 0.029) https://t.co/iMDSWnb5Dv https://t.co/ZwUKBkZbSL

Links:

Dr. John Cush RheumNow ( View Tweet)
NOVESA trial ziritaxestat (an autotaxin inhibitor) in 33 early diffuse systemic sclerosis pts. After 24 wks, ziritaxestat showed signif reduction in mRSS (–8.9 vs. –6.0 PBO; P=0.04). It was well tolerated & showed biologic effect w/ reduced LPA C18:2 https://t.co/GKC2TKOQhE https://t.co/AUaminOyiH

Links:

Dr. John Cush RheumNow ( View Tweet)
Large-scale genome-wide association study of R A (276,020 samples in 5 ancestral grps) identified 124 loci (P < 5 × 10−8), 34 being novel. Candidate genes showed essential roles for TNIP2, TNFRSF11A, WISP1 in RA. https://t.co/jk1ePlen5l https://t.co/aSIZYJ9oky

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×